Cohbar (OTCMKTS:CWBR) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.

Cohbar (OTCMKTS:CWBR) traded down $0.16 during midday trading on Friday, hitting $4.60. 22,976 shares of the stock traded hands, compared to its average volume of 50,842. Cohbar has a 12-month low of $1.60 and a 12-month high of $7.60.

TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at

About Cohbar

CohBar, Inc, a biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. Its lead MBT drug candidates include CB4209 and CB4211, which are in IND-enabling studies for the treatment of fatty liver disease, non-alcoholic steatohepatitis, obesity, and type 2 diabetes mellitus.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cohbar Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cohbar Inc and related companies with's FREE daily email newsletter.